Find clinical trials

The aim of this study is to evaluate the efficacy, safety and tolerability of BMB-101 in adults with either classic Absence Epilepsy (with or without Eyelid Myoclonia (EEM; Jeavons Syndrome)) or Developmental Epileptic Encephalopathy (DEE). A maximum of 20 participants will participate. Male or females, aged 18-65 yrs. Study duration is 4-5 months. For participants with classic absence epilepsy, there will be a 1-month screening period, then 8 weeks on BMB-101, and then a 1-month follow-up period. There will be 5 clinic visits and at least 4 phone calls. For participants with DEE, there will be a 1-month screening period, then 12 weeks on BMB-101, and then a 1-month follow-up period. There will be 6 clinic visits and at least 3 phone calls. The goal of the study is to assess the effects of BMB-101 in reducing the number of seizures. This will be done by comparing the frequency of seizures on EEGs and participant diaries.

The aim of this first-in-human (FIH) open-label, multi-site study is to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary clinical efficacy of BNT3212, including identification of the recommended dose of BNT3212 for use as monotherapy and with BNT327 as combination therapy, in adults with advanced solid tumors who have exhausted other treatment options.

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times per day, but this could change to once daily or another frequency). Depending on the part of the study, participants may also receive another study medicine. In the first part of the study, people with melanoma or other solid tumors may also receive encorafenib. Encorafenib comes as a capsule and is taken once per day. In the second part of the study, people with melanoma or other cancers with abnormalities in a gene called "BRAF" will receive PF-07799544 with other study medicines (for example, PF-07799933). Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.